...
首页> 外文期刊>Prostate Cancer and Prostatic Diseases >HLA class II antigen presentation by prostate cancer cells
【24h】

HLA class II antigen presentation by prostate cancer cells

机译:前列腺癌细胞对HLA II类抗原的呈递

获取原文
           

摘要

Prostate cancer is the second most commonly diagnosed cancer in men. Recent evidence suggests that reduced expression of target protein antigens and human leukocyte antigen (HLA) molecules is the predominant immune escape mechanism of malignant prostate tumor cells. The purpose of this study was to investigate the prospect of antigen specific immunotherapy against prostate cancer via the HLA class II pathway of immune recognition. Here, we show for the first time that prostate cancer cells express HLA class II proteins that are recognized by CD4+ T cells. Prostate tumor cells transduced with class II molecules efficiently presented tumor-associated antigens/peptides to CD4+ T cells. This data suggests that malignant prostate tumors can be targeted via the HLA class II pathway, and that class II-positive tumors could be employed for direct antigen presentation, and CD4+ T-cell mediated tumor immunotherapy.
机译:前列腺癌是男性中第二常见的癌症。最近的证据表明,靶蛋白抗原和人类白细胞抗原(HLA)分子的表达降低是恶性前列腺肿瘤细胞的主要免疫逃逸机制。这项研究的目的是研究通过HLA II类免疫识别途径针对前列腺癌进行抗原特异性免疫疗法的前景。在这里,我们首次显示前列腺癌细胞表达被CD4 + T细胞识别的II类HLA蛋白。用II类分子转导的前列腺肿瘤细胞有效地将肿瘤相关抗原/肽呈递给CD4 + T细胞。该数据表明,可以通过HLA II类途径靶向恶性前列腺肿瘤,并且II类阳性肿瘤可以用于直接抗原呈递和CD4 + T细胞介导的肿瘤免疫治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号